\-\ Texto\\:\\ \ \(0\)\
\-\ none\\ provided\\ initially\ \(0\)\
\-\ on\\ ct\\,\\ there\\ is\\ marked\\ and\\ diffuse\\ volume\\ loss\\,\\ ex\\ vacuole\\ dilatation\\ of\\ the\\ ventricles\\,\\ and\\ cystic\\ changes\\ of\\ the\\ basal\\ ganglia\\,\\ cerebellum\\ and\\ thalami\\.\ \(0\)\
\-\ follow\\-up\\ mr\\ again\\ reveals\\ diffuse\\ parenchymal\\ atrophy\\ with\\ cystic\\ degeneration\\ of\\ cerebellum\\,\\ cerebral\\ peduncles\\,\\ thalami\\ and\\ the\\ basal\\ ganglia\\.\\ on\\ spectroscopy\\,\\ there\\ is\\ a\\ significant\\ depression\\ of\\ the\\ naa\\ peak\\ with\\ a\\ resultant\\ increase\\ in\\ the\\ choline\\ peak\\.\\ lactate\\ is\\ also\\ present\\.\ \(0\)\
\-\ leigh\\'s\\ disease\\ \\(subacute\\ necrotizing\\ encephalopathy\\)\\.\ \(0\)\
\-\ profound\\ perinatal\\ asphyxia\ \(0\)\
\-\ mitochondrial\\ encephalopathy\\,\\ lactic\\ acidosis\\,\\ stroke\\-like\\ episodes\\ \\(melas\\)\ \(0\)\
\-\ glutaric\\ aciduria\\ type\\ i\ \(0\)\
\-\ wilson\\ disease\ \(1\)\
\-\ a\\ 2\\ month\\ old\\ male\\ with\\ mental\\ status\\ changes\\ for\\ evaluation\\ with\\ a\\ non\\-contrast\\ head\\ ct\\.\ \(0\)\
\-\ in\\ this\\ case\\,\\ there\\ is\\ extensive\\ white\\ matter\\ involvement\\ and\\ cerebral\\ atophy\\,\\ which\\ are\\ atypical\\ in\\ the\\ early\\ stages\\ of\\ leigh\\'s\\ syndrome\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ leigh\\:\\ 0\\.08651364505399056\ \(0\)\
\-\ thalami\\:\\ 0\\.07034681332655363\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.06576900379148022\ \(0\)\
\-\ peak\\:\\ 0\\.06358529026647151\ \(0\)\
\-\ vacuole\\:\\ 0\\.05761776747690522\ \(0\)\
\-\ glutaric\\:\\ 0\\.05761776747690522\ \(0\)\
\-\ ganglia\\:\\ 0\\.05716166231995009\ \(0\)\
\-\ cerebellum\\:\\ 0\\.055570852712400816\ \(0\)\
\-\ asphyxia\\:\\ 0\\.05308739374775525\ \(0\)\
\-\ melas\\:\\ 0\\.05308739374775525\ \(0\)\
\-\ aciduria\\:\\ 0\\.05308739374775525\ \(0\)\
\-\ atophy\\:\\ 0\\.05308739374775525\ \(0\)\
\-\ basal\\:\\ 0\\.050922058799194425\ \(0\)\
\-\ stroke\\-like\\:\\ 0\\.048557020018605276\ \(0\)\
\-\ lactic\\:\\ 0\\.047098565434852274\ \(0\)\
\-\ naa\\:\\ 0\\.04590692127280028\ \(0\)\
\-\ perinatal\\:\\ 0\\.04590692127280028\ \(0\)\
\-\ choline\\:\\ 0\\.04489940048961559\ \(0\)\
\-\ mitochondrial\\:\\ 0\\.04489940048961559\ \(0\)\
\-\ spectroscopy\\:\\ 0\\.04256819170570231\ \(0\)\
\-\ ex\\:\\ 0\\.04194524935404005\ \(0\)\
\-\ peduncles\\:\\ 0\\.0408533925915357\ \(0\)\
\-\ profound\\:\\ 0\\.03991809295989731\ \(0\)\
\-\ lactate\\:\\ 0\\.03910003320202799\ \(0\)\
\-\ cerebral\\:\\ 0\\.03869864708188328\ \(0\)\
\-\ wilson\\:\\ 0\\.037414875624890084\ \(0\)\
\-\ acidosis\\:\\ 0\\.036076350052040324\ \(0\)\
\-\ diffuse\\:\\ 0\\.033817090462422414\ \(0\)\
\-\ stages\\:\\ 0\\.03350744424740237\ \(0\)\
\-\ resultant\\:\\ 0\\.032737620484942345\ \(0\)\
\-\ depression\\:\\ 0\\.03259396749985231\ \(0\)\
\-\ necrotizing\\:\\ 0\\.03259396749985231\ \(0\)\
\-\ cystic\\:\\ 0\\.032217421009826906\ \(0\)\
\-\ changes\\:\\ 0\\.03201369903575243\ \(0\)\
\-\ atrophy\\:\\ 0\\.028815680893478725\ \(0\)\
\-\ subacute\\:\\ 0\\.02865818055636068\ \(0\)\
\-\ degeneration\\:\\ 0\\.02835412816659014\ \(0\)\
\-\ episodes\\:\\ 0\\.027584304404130122\ \(0\)\
\-\ parenchymal\\:\\ 0\\.02745358109232182\ \(0\)\
\-\ non\\-contrast\\:\\ 0\\.02726227140408579\ \(0\)\
\-\ again\\:\\ 0\\.02683652433107297\ \(0\)\
\-\ volume\\:\\ 0\\.026381666214738357\ \(0\)\
\-\ ventricles\\:\\ 0\\.026272731231174882\ \(0\)\
\-\ mental\\:\\ 0\\.02606016135074639\ \(0\)\
\-\ there\\:\\ 0\\.024935599146372327\ \(0\)\
\-\ \\'s\\:\\ 0\\.024628060370811045\ \(0\)\
\-\ atypical\\:\\ 0\\.024206082585685983\ \(0\)\
\-\ provided\\:\\ 0\\.024089017706166175\ \(0\)\
\-\ dilatation\\:\\ 0\\.023936123068423\ \(0\)\
\-\ increase\\:\\ 0\\.02342751507916282\ \(0\)\
\-\ i\\:\\ 0\\.023087024151820325\ \(0\)\
\-\ initially\\:\\ 0\\.022731897674935816\ \(0\)\
\-\ extensive\\:\\ 0\\.022335658316658468\ \(0\)\
\-\ matter\\:\\ 0\\.021990065166018286\ \(0\)\
\-\ reveals\\:\\ 0\\.021851292485588387\ \(0\)\
\-\ marked\\:\\ 0\\.02179659804329743\ \(0\)\
\-\ involvement\\:\\ 0\\.02047018729822102\ \(0\)\
\-\ early\\:\\ 0\\.020425875618578025\ \(0\)\
\-\ status\\:\\ 0\\.019936779877004273\ \(0\)\
\-\ \\,\\:\\ 0\\.01946281516790955\ \(0\)\
\-\ type\\:\\ 0\\.018827609335600723\ \(0\)\
\-\ white\\:\\ 0\\.01852355694583018\ \(0\)\
\-\ disease\\:\\ 0\\.018258007074715088\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.01817017641465191\ \(0\)\
\-\ mr\\:\\ 0\\.017746401777427673\ \(0\)\
\-\ month\\:\\ 0\\.016755650593468036\ \(0\)\
\-\ evaluation\\:\\ 0\\.016223782979260182\ \(0\)\
\-\ loss\\:\\ 0\\.01621218413378065\ \(0\)\
\-\ syndrome\\:\\ 0\\.015973245599572822\ \(0\)\
\-\ head\\:\\ 0\\.015840531441659454\ \(0\)\
\-\ ct\\:\\ 0\\.015624884358065921\ \(0\)\
\-\ significant\\:\\ 0\\.01501860883041976\ \(0\)\
\-\ is\\:\\ 0\\.014700412506790213\ \(0\)\
\-\ none\\:\\ 0\\.013854375862143834\ \(0\)\
\-\ present\\:\\ 0\\.012614436300207064\ \(0\)\
\-\ case\\:\\ 0\\.012218983221354712\ \(0\)\
\-\ 2\\:\\ 0\\.012026826774578734\ \(0\)\
\-\ also\\:\\ 0\\.011010585579543474\ \(0\)\
\-\ which\\:\\ 0\\.010425781615964372\ \(0\)\
\-\ a\\:\\ 0\\.010368622269767354\ \(0\)\
\-\ male\\:\\ 0\\.01009938260057172\ \(0\)\
\-\ on\\:\\ 0\\.009462627612619975\ \(0\)\
\-\ \\(\\:\\ 0\\.00944263694436419\ \(0\)\
\-\ \\)\\:\\ 0\\.00932729009298438\ \(0\)\
\-\ in\\:\\ 0\\.008262690787063822\ \(0\)\
\-\ are\\:\\ 0\\.007613554722415697\ \(0\)\
\-\ this\\:\\ 0\\.006281942570680608\ \(0\)\
\-\ and\\:\\ 0\\.00588264724615093\ \(0\)\
\-\ old\\:\\ 0\\.0057185267768774814\ \(0\)\
\-\ the\\:\\ 0\\.0054215405766127765\ \(0\)\
\-\ for\\:\\ 0\\.004765412736226896\ \(0\)\
\-\ of\\:\\ 0\\.0038073137515682496\ \(0\)\
\-\ with\\:\\ 0\\.0030589327082324114\ \(0\)\
\-\ \\.\\:\\ 0\\.0016241617822315287\ \(0\)\
